The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in patients with advanced hepatocellular carcinoma (HCC).
Jennifer J. Knox
Consultant or Advisory Role - Novartis (U)
Honoraria - AVEO; Pfizer; Pfizer
Research Funding - Bayer; Bayer; Pfizer; Pfizer
Rui Qin
No relevant relationships to disclose
Jonathan R. Strosberg
Consultant or Advisory Role - Novartis
Honoraria - Genentech (B)
Research Funding - Amgen; Novartis; Pfizer
Andreas Kaubisch
No relevant relationships to disclose
Anthony B. El-Khoueiry
No relevant relationships to disclose
Tanios B Bekaii-Saab
Consultant or Advisory Role - Genentech
Charles Erlichman
No relevant relationships to disclose